. 2023 Sep 22;41(41):5979–5986. doi: 10.1016/j.vaccine.2023.08.041

Table 2.

Subgroup analysis of PCV13 protection effectiveness.

Characteristics	Group	No Vaccine Exposure			Vaccine Exposure			Hazard Ratio (95% CI)
		Observation time (year)	No. of Events	Incidence density (1/1000 py)	Observation time (year)	No. of Events	Incidence density (1/1000 py)	Hazard Ratio (95% CI)
Vaccination procedure	Complete	10167.5	285	0.02803	10289.9	237	0.02303	0.82 (0.69–0.98) *
	Uncomplete	1164.6	32	0.02747	1163.7	27	0.02320	0.84 (0.51–1.41)
Hospitalization or not	Hospitalized	10647.2	97	0.00927	10526.5	68	0.00646	0.70 (0.51–0.95) ^*
	Outpatient	10177.5	280	0.02751	10301.9	229	0.02223	0.81 (0.68–0.96) ^*
Follow-up time	<1y	773.7	181	0.23393	754.8	135	0.17885	0.77 (0.62–0.97) ^*
	1 to < 2y	2729.1	81	0.02968	2706.4	76	0.02808	0.95 (0.7–1.3)
	2-3y	4555.7	19	0.00417	4595.2	22	0.00479	1.15 (0.62–2.12)

p < 0·01.